المؤلفون: O. M. Drapkina, A. V. Kontsevaya, A. M. Kalinina, S. M. Avdeev, M. V. Agaltsov, L. M. Alexandrova, A. A. Antsiferova, D. M. Aronov, N. M. Akhmedzhanov, Yu. A. Balanova, T. V. Balakhonova, S. A. Berns, M. V. Bochkarev, E. V. Bochkareva, M. V. Bubnova, A. V. Budnevsky, M. G. Gambaryan, V. M. Gorbunov, B. E. Gorny, A. Yu. Gorshkov, N. G. Gumanova, V. A. Dadaeva, L. Yu. Drozdova, V. A. Egorov, S. O. Eliashevich, A. I. Ershova, E. S. Ivanova, A. E. Imaeva, P. V. Ipatov, A. D. Kaprin, N. S. Karamnova, Zh. D. Kobalava, A. O. Konradi, O. V. Kopylova, L. S. Korostovtseva, M. B. Kotova, M. S. Kulikova, E. A. Lavrenova, O. V. Lischenko, M. V. Lopatina, Yu. V. Lukina, M. M. Lukyanov, I. V. Mayev, M. N. Mamedov, S. V. Markelova, S. Yu. Martsevich, V. A. Metelskaya, A. N. Meshkov, O. Yu. Milushkina, D. K. Mukaneeva, A. O. Myrzamatova, D. V. Nebieridze, D. O. Orlov, E. A. Poddubskaya, M. V. Popovich, O. E. Popovkina, V. I. Potievskaya, G. G. Prozorova, Yu. S. Rakovskaya, O. P. Rotar, I. A. Rybakov, Yu. V. Sviryaev, I. A. Skripnikova, N. A. Skoblina, M. I. Smirnova, V. V. Starinsky, S. N. Tolpygina, E. V. Usova, Zh. V. Khailova, S. A. Shalnova, R. N. Shepel, V. N. Shishkova, I. S. Yavelov, B. U. Mardanov

المصدر: Кардиоваскулярная терапия и профилактика, Vol 21, Iss 4 (2022)

مصطلحات موضوعية: профилактика, хронические неинфекционные заболевания, национальное руководство, Diseases of the circulatory (Cardiovascular) system, RC666-701

وصف الملف: electronic resource

العلاقة: https://cardiovascular.elpub.ru/jour/article/view/3235Test; https://doaj.org/toc/1728-8800Test; https://doaj.org/toc/2619-0125Test

الوصول الحر: https://doaj.org/article/83300086b47843efba984b9a0791df00Test

المؤلفون: R. A. Bontsevich, A. A. Gavrilova, Y. R. Vovk, A. V. Adonina, N. Y. Goncharova, G. G. Prozorova, O. G. Kompaniets, V. O. Barysheva, G. G. Ketova, E. N. Bochanova, E. V. Mironenko, T. M. Shagiyeva, A. A. Kirichenko, I. F. Krotkova, E. A. Shabanov, U. M. Tilekeyeva, E. V. Luchinina, I. P. Galkina, M. L. Maksimov, V. A. Nevzorova

المصدر: Medičnì Perspektivi, Vol 25, Iss 1, Pp 59-65 (2020)

مصطلحات موضوعية: community-acquired pneumonia, pharmacotherapy, clinical recommendations, doctors, students, pharmacoepidemiology, Medicine

وصف الملف: electronic resource

العلاقة: http://journals.uran.ua/index.php/2307-0404/article/view/200402Test; https://doaj.org/toc/2307-0404Test

الوصول الحر: https://doaj.org/article/4d2016b75bc441cfb0fed61c98bfe164Test

المؤلفون: L. V. Tribuntceva, A. V. Budnevsky, G. G. Prozorova, O. N. Choporov, S. A. Kozhevnikova, I. A. Olysheva

المصدر: Sechenov Medical Journal. 14:27-38

مصطلحات موضوعية: Modeling and Simulation

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0c22ab188b238bb1877d481ec938933aTest
https://doi.org/10.47093/2218-7332.2023.14.1.27-38Test

المؤلفون: S. N. Avdeev, A. S. Belevskiy, Z. R. Aisanov, V. V. Arkhipov, I. V. Leshchenko, S. I. Ovcharenko, A. I. Sinopal’nikov, A. A. Vizel’, A. V. Emel’yanov, A. V. Zhestkov, K. A. Zykov, N. A. Kuzubova, G. G. Prozorova, B. A. Chernyak, N. L. Shaporova, E. I. Shmelev, С. Н. Авдеев, А. C. Белевский, З. Р. Айсанов, В. В. Архипов, И. В. Лещенко, С. И. Овчаренко, А. И. Синопальников, А. А. Визель, А. В. Емельянов, А. В. Жестков, К. А. Зыков, Н. А. Кузубова, Г. Г. Прозорова, Б. А. Черняк, Н. Л. Шапорова, Е. И. Шмелев

المصدر: PULMONOLOGIYA; Том 28, № 3 (2018); 368-380 ; Пульмонология; Том 28, № 3 (2018); 368-380 ; 2541-9617 ; 0869-0189 ; 10.18093/0869-0189-2018-28-3

مصطلحات موضوعية: тиотропий / олодатерол, exacerbations, prevention, inhalational therapy, long-acting bronchodilators, tiotropium, inhaled corticosteroids, tiotropium/olodaterol, обострения, профилактика, ингаляционные препараты, бронходилататоры длительного действия, тиотропий, ингаляционные глюкокортикостероиды

وصف الملف: application/pdf

العلاقة: https://journal.pulmonology.ru/pulm/article/view/1007/844Test; GOLD 2018. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2018 Report. Available at: https://goldcopd.orgTest [Accessed June 04, 2018].; Groenewegen K.H., Schols A.M., Wouters E.F. Mortality and mortality related factors after hospitalization for acute exacerbation of COPD. Chest. 2003; 124 (2): 459–467. DOI:10.1378/chest.124.2.459.; Buhl R., Criée C.P., Kardos P. et al. A year in the life of German patients with COPD: the DACCORD observational study. Int. J. Chron. Obstruct. Pulmon. Dis. 2016; 11 (1): 1639–1646. DOI:10.2147/COPD.S112110.; Arkhipov V., Arkhipova D., Miravitlles M. et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 3255–3262. DOI:10.2147/COPD.S142997.; Hurst J., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363 (12): 1128–1138. DOI:10.1056/NEJMoa0909883.; Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370 (9589): 786–796. DOI:10.1016/S0140-6736(07)61382-8.; Celli B.R., Barnes P.J. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29 (6): 1224–1238. DOI: 0.1183/09031936.00109906.; Seemungal T., Harper-Owen R., Bhowmik A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164 (9): 1618–1623. DOI:10.1164/ajrccm.164.9.2105011.; Vedel-Krogh S., Nielsen S.F., Lange P. et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am. J. Respir. Crit. Care Med. 2016; 193 (9): 965–974. DOI:10.1164/rccm.201509-1869OC.; Couillard S., Larivee P., Courteau J., Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017; 151 (2): 366–373. DOI:10.1016/j.chest.2016.10.003.; Miravitlles M., D’Urzo A., Singh D., Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review. Respir. Res. 2016; 17 (1): 112. DOI:10.1186/s12931-016-0425-5.; Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines. Arch. Bronconeumol. 2012; 48 (3): 86–98. DOI:10.1016/j.arbres.2011.10.007.; Calverley P., Pauwels R., Löfdahl C.G. et al. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur. Respir. J. 2005; 26 (3): 406–413. DOI:10.1183/09031936.05.00143404.; Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31 (2): 416–469. DOI:10.1183/09031936.00099306.; Rennard S., Leidy N.K. Definition and severity of COPD exacerbations. In: Wedzicha W., Martinez F., eds. Exacerbations of Chronic Obstructive Pulmonary Disease (COPD). New York: Informa Healthcare; 2009.; Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010; 363 (12): 1128–1138. DOI:10.1056/NEJMoa0909883.; Suissa S. Run-in bias in randomised trials: the case of COPD medications. Eur. Respir. J. 2017; 22; 49 (6): pii: 1700361. DOI:10.1183/13993003.00361-2017.; Halpin D.M., Kerkhof M., Soriano J.B. et al. Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy. Respir. Res. 2016; 17 (1): 120. DOI:10.1186/s12931-016-0433-5.; Wedzicha J.A., Banerji D., Chapman K.R. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N. Engl. J. Med. 2016; 374 (23): 2222–2234. DOI: 0.1056/NEJMoa1516385.; Taskin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Eng. J. Med. 2008; 359 (15): 1543–1554. DOI:10.1056/NEJMoa0805800.; Bateman E.D., Tashkin D., Siafatas N. et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients. Respir. Med. 2010; 104 (10): 1460–1472. DOI:10.1016/j.rmed.2010.06.004.; Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus Salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364 (12): 1093–1103. DOI:10.1056/NEJMoa1008378.; Decramer L., Chapman J.R., Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir. Med. 2013; 1 (7): 524–533. DOI: 0.1016/S2213-2600(13)70158-9.; Chong J., Karner C., Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (9): CD009157. DOI:10.1002/14651858.CD009157.; Wedzicha J.A., Calverley P.M., Seemungal T.A. et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177 (1): 19–26. DOI:10.1164/rccm.200707-973OC.; Powrie D.J., Wilkinson T.M.A., Donaldson G.C. et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Respir. J. 2007; 30 (3): 472–478. DOI:10.1183/09031936.00023907.; Horita N., Goto A., Shibata Y. et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst. Rev. 2017; (2): CD012066. DOI:10.1002/14651858.CD012066.; Rodrigo G., Price D., Anzueto A. et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2017; (12): 907–922. DOI:10.2147/COPD.S130482.; Zhong N., Wang C., Zhou X., et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; (10): 1015–1026. DOI:10.2147/COPD.S84436.; Wedzicha J.A., Decramer M., L. Ticker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med., 2013; 1 (3): 199–209. DOI:10.1016/S2213-2600(13)70052-3.; Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J. 2015; 45 (4): 969–979. DOI:10.1183/09031936.00136014.; Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494. DOI:10.1183/09031936.00200212.; Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir. Med. 2014; 2 (6): 472–486. DOI:10.1016/S2213-2600(14)70065-7.; Martinez F.J., Rabe K.F., Ferguson G.T. et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017; 151 (2): 340–357. DOI:10.1016/j.chest.2016.11.028.; Singh D., Ferguson G.T., Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir. Med. 2015; 109 (10): 1312–1319. DOI:10.1016/j.rmed.2015.08.002.; Mahler D.A., Decramer M., D'Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43 (6): 1599–609. DOI:10.1183/09031936.00124013.; Beeh K.M., Westerman J., Kirsten A.M. et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm. Pharm. Ther. 2015; 32: 53–59. DOI:10.1016/j.pupt.2015.04.002.; Beeh K.M., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Respir. Med. 2014; 108 (4): 584–592. DOI:10.1016/j.rmed.2014.01.006.; Calverley P.M.A., Anzueto A.R., Carter K. et al. Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. Lancet Respir. Med. 2018; 6 (5): 337–344. DOI:10.1016/S2213-2600(18)30102-4.; Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20. / Aisanov Z.R., Avdeev S.N., Arkhipov V.V. et al. National clinical guidelines on diagnosis and treatment of chronic obstructive pulmonary disease: a clinical decision-making algorithm. Russian Pulmonology. 2017; 27 (1): 13–20. DOI:10.18093/0869-0189-2017-27-1-13-20 (in Russian).; Aisanov Z., Avdeev S., Arkhipov V. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. Int. J. Chron. Obstruct. Pulmon. Dis. 2018; 13: 183–187. DOI:10.2147/COPD.S153770.; Washko G.R., Fan V.S., Ramsey S.D. et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 177 (2): 164–169. DOI:10.1164/rccm.200708-1194OC.; Beeh K.M., Burgel P.R., Franssen F.M.E. et al. How do dual long-acting bronchodilators prevent exacerbations of chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2017; 196 (2): 139–149. DOI:10.1164/rccm.201609-1794CI.; Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J. 2013; 22 (1): 92–100. DOI:10.4104/pcrj.2012.00092.; Ernst P., Saad N., Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur. Respir. J. 2015; 45 (2): 525–537. DOI:10.1183/09031936.00128914.; Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10 (1): 2535–2548. DOI:10.2147/COPD.S93321.; Watz H., Tetzlaff K., Wouters E.F. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir. Med. 2016; 4 (5): 390–398. DOI:10.1016/S2213-2600(16)00100-4.; Magnussen H., Disse B., Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N. Engl. J. Med. 2014; 371 (14): 1285–1294. DOI:10.1056/NEJMoa1407154.; https://journal.pulmonology.ru/pulm/article/view/1007Test

الإتاحة: https://doi.org/10.18093/0869-0189-2018-28-3-368-380Test
https://doi.org/10.18093/0869-0189-2018-28-3Test
https://doi.org/10.1378/chest.124.2.459Test
https://doi.org/10.2147/COPD.S112110Test
https://doi.org/10.2147/COPD.S142997Test
https://doi.org/10.1056/NEJMoa0909883Test
https://doi.org/10.1016/S0140-6736Test(07)61382-8
https://doi.org/10.1164/ajrccm.164.9.2105011Test
https://doi.org/10.1164/rccm.201509-1869OCTest
https://doi.org/10.1016/j.chest.2016.10.003Test

المؤلفون: O. M. Drapkina, A. V. Kontsevaya, A. M. Kalinina, S. M. Avdeev, M. V. Agaltsov, L. M. Alexandrova, A. A. Antsiferova, D. M. Aronov, N. M. Akhmedzhanov, Yu. A. Balanova, T. V. Balakhonova, S. A. Berns, M. V. Bochkarev, E. V. Bochkareva, M. V. Bubnova, A. V. Budnevsky, M. G. Gambaryan, V. M. Gorbunov, B. E. Gorny, A. Yu. Gorshkov, N. G. Gumanova, V. A. Dadaeva, L. Yu. Drozdova, V. A. Egorov, S. O. Eliashevich, A. I. Ershova, E. S. Ivanova, A. E. Imaeva, P. V. Ipatov, A. D. Kaprin, N. S. Karamnova, Zh. D. Kobalava, A. O. Konradi, O. V. Kopylova, L. S. Korostovtseva, M. B. Kotova, M. S. Kulikova, E. A. Lavrenova, O. V. Lischenko, M. V. Lopatina, Yu. V. Lukina, M. M. Lukyanov, I. V. Mayev, M. N. Mamedov, S. V. Markelova, S. Yu. Martsevich, V. A. Metelskaya, A. N. Meshkov, O. Yu. Milushkina, D. K. Mukaneeva, A. O. Myrzamatova, D. V. Nebieridze, D. O. Orlov, E. A. Poddubskaya, M. V. Popovich, O. E. Popovkina, V. I. Potievskaya, G. G. Prozorova, Yu. S. Rakovskaya, O. P. Rotar, I. A. Rybakov, Yu. V. Sviryaev, I. A. Skripnikova, N. A. Skoblina, M. I. Smirnova, V. V. Starinsky, S. N. Tolpygina, E. V. Usova, Zh. V. Khailova, S. A. Shalnova, R. N. Shepel, V. N. Shishkova, I. S. Yavelov

المصدر: Cardiovascular Therapy and Prevention. 21:3235

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Education

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::2f4b2626707d95671d89b5de5b8a3f92Test
https://doi.org/10.15829/1728-8800-2022-3235Test

المؤلفون: S. A. Kozhevnikova, N. E. Nekhaenko, L. V Tribuntseva, V. T. Burlachuk, M. G. Bubnova, N. I. Ostroushko, Yu. A. Sharapova, O. M. Drapkina, G. G. Prozorova, A. V. Razvorotnev

المصدر: Profilakticheskaya meditsina. 21:77

مصطلحات موضوعية: 03 medical and health sciences, 0302 clinical medicine, business.industry, Health Policy, Public Health, Environmental and Occupational Health, Medicine, 030212 general & internal medicine, 030204 cardiovascular system & hematology, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::0833b1f9c38d486160afb7285fcb7375Test
https://doi.org/10.17116/profmed20182105177Test

المؤلفون: G G, Prozorova, S V, Simonaĭtes, V T, Burlachuk

المصدر: Terapevticheskii arkhiv. 77(1)

مصطلحات موضوعية: Male, Vaccination, Middle Aged, Prognosis, Injections, Intramuscular, Severity of Illness Index, Pulmonary Disease, Chronic Obstructive, Influenza Vaccines, Forced Expiratory Volume, Influenza, Human, Humans, Female, Follow-Up Studies, Retrospective Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::3c5955216880a872a9301d962b363129Test
https://pubmed.ncbi.nlm.nih.gov/15759457Test

المؤلفون: G G, Prozorova, V P, Sil'vestrov, S I, Simvolokov, A V, Nikitin

المصدر: Terapevticheskii arkhiv. 69(10)

مصطلحات موضوعية: Adult, Evaluation Studies as Topic, Chronic Disease, Humans, Actihaemyl, Drug Therapy, Combination, Laser Therapy, Disseminated Intravascular Coagulation, Middle Aged, Bronchitis, Respiratory Insufficiency, Combined Modality Therapy, Piracetam

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::363182749b7eba4d65048603efe3680fTest
https://pubmed.ncbi.nlm.nih.gov/9471786Test